Cardiac troponin T in end-stage renal disease patients undergoing chronic maintenance hemodialysis.

sis usually involve chaotropic agents such as guanidinium chloride and (or) detergents for the dissociation of iron at an acidic pH from transferrin. Reduction is achieved with various reducing compounds such as ascorbic acid, hydroxylamine, thioglycolic acid, and others. Among these, ascorbic acid is unique in its property not only to reduce but also to chelate iron. This property appears to be the reason for the published finding that reagents containing ascorbic acid are prone to overrecovery of serum iron liberated from nontransferrin sources, especially from Fe-dextran that is frequently administered parenterally to hemodialysis patients (1). On the other hand, reagents involving other reductants are more sensitive to interference by iron-chelating substances, such as ED’FA, that diminish and (or) slow the color reaction. With the Roche Unimate 7 iron reagent, which has hydroxylamine as